4D Molecular Therapeutics Newsroom

4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC Capital

Dow JonesJul 22 10:07 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaJul 22 09:56 ET

Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)

TipRanksJul 22 02:02 ET

Strong Buy Rating for 4D Molecular Therapeutics Backed by Promising WAMD Treatment Efficacy and Safety

TipRanksJul 18 05:17 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaJul 17 15:02 ET

Buy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene Therapy

TipRanksJul 17 13:09 ET

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)

TipRanksJul 17 12:07 ET

Maintaining Buy Rating on 4D Molecular Therapeutics: 4D-150 Poised for Success With Superior Safety and Efficacy in Wet AMD Treatment

TipRanksJul 12 08:07 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaJun 26 11:14 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaJun 7 09:47 ET

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)

TipRanksMay 14 13:40 ET

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)

TipRanksMay 14 05:06 ET

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)

TipRanksMay 13 07:46 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaMay 13 06:46 ET

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)

TipRanksMay 10 07:01 ET

Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)

TipRanksMay 10 05:56 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaApr 15 13:14 ET

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40

BenzingaApr 15 13:14 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaApr 15 07:08 ET

RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TipRanksApr 15 07:00 ET